Plain-English translation of NCT07616375 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a safety study of HSK31858, a new medication designed to help people with non-cystic fibrosis bronchiectasis—a chronic lung disease where the airways become damaged and scarred. The trial will follow about 669 people for 96 weeks to carefully monitor how well the medication is tolerated and whether it causes any side effects. This medication is being tested in people who have already participated in an earlier trial and tolerated it well.
Researchers want to understand the long-term safety of this treatment in people with this chronic lung condition. By collecting safety data over nearly two years, they hope to determine whether this medication can be a reliable option for patients who need ongoing treatment.
You likely qualify if…
You likely don't qualify if…
You will take HSK31858 40mg daily for 96 weeks (about 2 years). You will visit the study site regularly so doctors can monitor your health, check for any side effects, and make sure the treatment is working safely for you. During these visits, you may have blood tests, breathing tests, or other check-ups to track how you're doing.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Enrollment target
~669 participants
Started
September 2025
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guan Wei Jie
Haisco Pharmaceutical Group Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.